Garuda Therapeutics, a Cambridge, Mass.-based company creating off-the-shelf, durable blood stem cell therapies, raised $72m in Series A financing.
The round was led by Aisling Capital, Northpond Ventures and Orbimed, supported by Cormorant Asset Management, Ridgeback Capital Investments, Monashee Investment Management, Sectoral Asset Management, National Resilience, Inc. (Resilience), Mass General Brigham Ventures, among others.
Aisling Capital, Northpond Ventures, Orbimed, Cormorant Asset Management, Ridgeback Capital Investments, Monashee Investment Management, Sectoral Asset Management, National Resilience, Mass General Brigham Ventures,
Founded by Dhvanit Shah, Ph.D., who previously served as Principal Faculty of Harvard Stem Cell Institute, Associate Member of the Broad Institute of MIT and Harvard, and Principal Investigator at Brigham and Women’s Hospital, David Scadden, M.D. and Sean Morrison, Ph.D., Garuda is developing an off-the-shelf hematopoietic stem cell platform that will eliminate dependency on donor or patient cells. The platform for generating off-the-shelf, self-renewing blood stem cells is designed to provide patients with rapid and broad access to consistent, durable, HLA-matched transgene-free blood stem cell therapies. Currently, patients seeking a blood stem cell transplant, must find a suitable human donor as a source of blood stem cells. The technology has the potential to address, and possibly cure, more than 70 diseases. Its pipeline includes therapeutic indications in hematologic malignancies, sickle cell disease, β-thalassemia, bone marrow failure diseases, among others.
Eric Aguiar, M.D. of Aisling; Carl Gordon, Ph.D., CFA, of OrbiMed; Shaan C. Gandhi, M.D., D.Phil, of Northpond; and Rahul Singhvi, Sc.D., of Resilience are part of its board of directors.